121 related articles for article (PubMed ID: 23359189)
1. Serum vaspin may be a good indicator of fibrosis in chronic hepatitis C and is not altered by antiviral therapy.
Kukla M; Waluga M; Sawczyn T; Berdowska A; Kajor M; Boryczka G; Stygar D; Gabriel A; Zwirska-Korczala K; Hartleb M
Pol J Pathol; 2012 Dec; 63(4):213-20. PubMed ID: 23359189
[TBL] [Abstract][Full Text] [Related]
2. Chemerin, vaspin and insulin resistance in chronic hepatitis C.
Kukla M; Zwirska-Korczala K; Gabriel A; Waluga M; Warakomska I; Szczygiel B; Berdowska A; Mazur W; Wozniak-Grygiel E; Kryczka W
J Viral Hepat; 2010 Sep; 17(9):661-7. PubMed ID: 20002564
[TBL] [Abstract][Full Text] [Related]
3. Serum omentin and vaspin levels in cirrhotic patients with and without portal vein thrombosis.
Kukla M; Waluga M; Żorniak M; Berdowska A; Wosiewicz P; Sawczyn T; Bułdak RJ; Ochman M; Ziora K; Krzemiński T; Hartleb M
World J Gastroenterol; 2017 Apr; 23(14):2613-2624. PubMed ID: 28465646
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C.
Lorenzo-Zúñiga V; Bartolí R; Masnou H; Montoliu S; Morillas RM; Planas R
Dig Dis Sci; 2007 Nov; 52(11):3245-50. PubMed ID: 17410466
[TBL] [Abstract][Full Text] [Related]
5. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
[TBL] [Abstract][Full Text] [Related]
6. Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Pazgan-Simon M; Kukla M; Zuwała-Jagiełło J; Derra A; Bator M; Menżyk T; Lekstan A; Grzebyk E; Simon K
PLoS One; 2020; 15(1):e0227459. PubMed ID: 31935230
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease.
Aktas B; Yilmaz Y; Eren F; Yonal O; Kurt R; Alahdab YO; Celikel CA; Ozdogan O; Imeryuz N; Kalayci C; Avsar E
Metabolism; 2011 Apr; 60(4):544-9. PubMed ID: 20580037
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment serum interferon gamma inducible protein-10 as biomarker of fibrosis and predictor of virological response in genotype 4 hepatitis C virus infection.
Khalifa KA; Radwan WM; Attallah KM; Hosney H; Eed EM
Acta Gastroenterol Belg; 2014 Dec; 77(4):401-7. PubMed ID: 25682629
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood and hepatic Toll-like receptor 7 expression and interferon lambda 1 levels in chronic hepatitis C: Relation to virus replication and liver injury.
El Aggan H; Farahat N; El Deeb N; Zeid A; El-Shendidi A
Microb Pathog; 2019 Jun; 131():65-74. PubMed ID: 30926417
[TBL] [Abstract][Full Text] [Related]
10. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
Terrier B; Carrat F; Geri G; Pol S; Piroth L; Halfon P; Poynard T; Souberbielle JC; Cacoub P
J Hepatol; 2011 Oct; 55(4):756-61. PubMed ID: 21334402
[TBL] [Abstract][Full Text] [Related]
11. Association between hepatic angiogenesis and serum adipokine profile in non-obese chronic hepatitis C patients.
Kukla M; Berdowska A; Gabriel A; Sawczyn T; Mazur W; Sobala-Szczygieł B; Grzonka D; Zajęcki W; Tomaszek K; Bułdak RJ; Zwirska-Korczala K
Pol J Pathol; 2011 Dec; 62(4):218-28. PubMed ID: 22246907
[TBL] [Abstract][Full Text] [Related]
12. Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Huang JF; Huang CF; Yu ML; Dai CY; Huang CI; Yeh ML; Hsieh MH; Yang JF; Hsieh MY; Lin ZY; Chen SC; Chuang WL
J Gastroenterol Hepatol; 2011 Mar; 26(3):530-5. PubMed ID: 21332548
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.
Saitou Y; Shiraki K; Yamanaka Y; Yamaguchi Y; Kawakita T; Yamamoto N; Sugimoto K; Murata K; Nakano T
World J Gastroenterol; 2005 Jan; 11(4):476-81. PubMed ID: 15641129
[TBL] [Abstract][Full Text] [Related]
14. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study.
Manolakopoulos S; Bethanis S; Liapi C; Stripeli F; Sklavos P; Margeli A; Christidou A; Katsanika A; Vogiatzakis E; Tzourmakliotis D; Theocharis S
BMC Gastroenterol; 2007 May; 7():17. PubMed ID: 17540037
[TBL] [Abstract][Full Text] [Related]
15. Is serum angiotensin converting enzyme level a useful non-invasive marker for liver fibrosis in patients with chronic hepatitis C?
Akar T
Rev Assoc Med Bras (1992); 2018 Mar; 64(3):224-229. PubMed ID: 29641775
[TBL] [Abstract][Full Text] [Related]
16. A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon-alpha-2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C (PRACTICE).
Bourgeois S; Deltenre P; Delwaide J; Henrion J; Adler M; Langlet P; Mulkay JP; Nevens F; Brixko C; Moreno C
Acta Gastroenterol Belg; 2014 Dec; 77(4):393-400. PubMed ID: 25682628
[TBL] [Abstract][Full Text] [Related]
17. Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.
Patel K; Remlinger KS; Walker TG; Leitner P; Lucas JE; Gardner SD; McHutchison JG; Irving W; Guha IN
Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2113-20.e1-3. PubMed ID: 24815325
[TBL] [Abstract][Full Text] [Related]
18. Serum cystatin C: a non-invasive marker of liver fibrosis or of current liver fibrogenesis in chronic hepatitis C? .
Ladero JM; Cárdenas MC; Ortega L; González-Pino A; Cuenca F; Morales C; Lee-Brunner A
Ann Hepatol; 2012; 11(5):648-51. PubMed ID: 22947524
[TBL] [Abstract][Full Text] [Related]
19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
20. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.
Stättermayer AF; Rutter K; Beinhardt S; Scherzer TM; Stadlmayr A; Hofer H; Wrba F; Steindl-Munda P; Krebs M; Datz C; Trauner M; Ferenci P
J Hepatol; 2012 Sep; 57(3):492-8. PubMed ID: 22634340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
